Bleeding disorders: Characterization, dental considerations and management

Journal of the Canadian Dental Association

Volumn 72, Issue 9, 2006, Pages

  Israels, Sara ^a   Schwetz, Nora ^b   Boyar, Ron ^c   McNicol, Archie ^c,d  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HEALTH SCIENCES CENTRE   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d NONE   (Canada)

Author keywords

Blood coagulation disorders complications; Blood coagulation physiology

Indexed keywords

ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; HEMOSTATIC AGENT;

BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; DENTAL CARE; HEMOPHILIA A; HUMAN; ORAL BLEEDING; ORAL SURGERY; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTOPERATIVE HEMORRHAGE; REVIEW; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE;

ANTICOAGULANTS; ANTIFIBRINOLYTIC AGENTS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BLOOD LOSS, SURGICAL; DENTAL CARE FOR CHRONICALLY ILL; HEMOPHILIA A; HEMOSTATICS; HUMANS; ORAL HEMORRHAGE; ORAL SURGICAL PROCEDURES; POSTOPERATIVE HEMORRHAGE; THROMBOCYTOPENIA; VON WILLEBRAND DISEASE;

EID: 33751002041     PISSN: 14882159     EISSN: 14882159     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Mann KG. Biochemistry and physiology of blood coagulation. Thromb Haemost 1999; 82(2):165-174.
2. McNicol A, Israels SJ, Gerrard JM. Platelets. In: Poller L, editor. Recent advances in blood coagulation. No. 6. Churchill Livingstone; 1993. p. 17-79.
3. Morrissey JH. Tissue factor: an enzyme cofactor and a true receptor. Thromb Haemost 2001; 86(1):66-74.
4. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003; 1(7):1504-14.
5. Hartwig J, Italiano J Jr. The birth of the platelet. J Thromb Haemost 2003; 1(7):1580-6.
6. McNicol A, Gerrard JM. Platelet morphology, aggregation, and secretion. In: Lapetina EG, editor. Advances in molecular and cell biology. London: JAI Press Inc.; 1997. p. 1-29.
7. Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 2003; 1(7):1335-42.
8. Freyssinet JM. Cellular microparticles: what are they bad or good for? J Thromb Haemost 2003; 1(7):1655-62.
9. Quinn MJ, Byzova TV, Qin J, Topol EJ, Plow EF. Integrin alphaIIbbeta3 and its antagonism. Arterioscler Thromb Vasc Biol 2003; 23(6):945-52.
10. Hambleton J. Diagnosis and incidence of inherited von Willebrand disease. Curr Opin Hematol 2001; 8(5):306-11.
11. Israels LG, Israels ED. Von Willebrand Factor. In: Israels LG, Israels ED, editors. Mechanisms in hematology. 3rd ed. Concord: Core Publishing; 2002. p. 341-8.
12. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997; 90(7):2515-21.
13. Kohler M, Hellstern P, Miyashita C, von Blohn G, Wenzel E. Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP). Thromb Haemost 1986; 55(1):108-11.
14. Battle J, Noya MS, Giangrande P, Lopez-Fernandez MF. Advances in the therapy of von Willebrand disease. Haemophilia 2002; 8(3):301-7.
15. Berntop E, Nilsson IM. Use of a high-purity factor VIII concentrate (Hemate P) in von Willebrand's disease. Vox Sang 1989; 56(4):212-7.
16. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross-over randomized trial. Blood 1992; 79(12):3130-7.
17. Bolton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet 2003; 361(9371):1801-9.
18. Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344(23):1773-9.
19. Gill JC. The role of genetics in inhibitor formation. Thromb Haemost 1999; 82(2):500-4.
20. Peyvandi F, Mannucci PM. Rare coagulation disorders. Thromb Haemost 1999; 82(4):1207-14.
21. Di Paola J, Nugent D, Young G. Current therapy for rare factor deficiencies. Haemophilia 2001; 7(Suppl1):16-22.
22. Israels LG, Israels ED. Vitamin K. In: Israels LG, Israels ED, editors. Mechanisms in hematology. 3rd ed. Concord: Core Publishing; 2002. p. 349-54.
23. Chai SJ, Macik BG. Improving the safety profile of warfarin. Semin Hematol 2002; 39(3):179-86.
24. Schafer AI. Low-molecular-weight heparin - an opportunity for home treatment of venous thrombosis. N Engl J Med 1996; 334(11):724-5.
25. O'Shea SI, Ortel TL. Issues in the utilization of low molecular weight heparins. Semin Hematol 2002; 39(3):172-8.
26. Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004; 103(2):390-8.
27. Geddis AE, Kaushansky K. Inherited thrombocytopenias: toward a molecular understanding of disorders of platelet production. Curr Opin Pediatr 2004; 16(1):15-22.
28. Clemetson KJ. Platelet glycoproteins and their role in diseases. Transfus Clin Biol 2001; 8(3):155-62.
29. Cattaneo M. Inherited platelet-based bleeding disorders. J Thromb Haemost 2003; 1(7):1628-36.
30. Almeida AM, Khair K, Hann I, Leisner R. The use of recombinant factor VIIa in children with inherited platelet function disorders. Br J Haematol 2003; 121(3):477-81.
31. Bellucci S, Caen J. Molecular basis of Glanzmann's Thrombasthenia and current strategies in treatment. Blood Rev 2002; 16(3):193-202.
32. George JN, Caen JP, Nurden AT. Glanzmann's thrombasthenia: the spectrum of clinical disease. Blood 1990; 75(7):1383-95.
33. Hayward CP, Rivard GE, Kane WH, Drouin J, Zheng S, Moore JC, and other. An autosomal dominant, qualitative platelet disorder associated with multimerin deficiency, abnormalities in platelet factor V, thrombospondin, von Willebrand factor, and fibrinogen and an epinephrine aggregation defect. Blood 1996; 87(12):4967-78.
34. McNicol A, Israels SJ. Platelet dense granules: structure, function and implications for haemostasis. Thromb Res 1999; 95(1):1-18.
35. Zondor SD, George JN, Medina PJ. Treatment of drug-induced thrombocytopenia. Expert Opin Drug Saf 2002; 1(2):173-80.
36. George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA, Osborne S, and other. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129(11):886-90.
37. Poon M-C, Israels S, Lillicrap D. Clinical practice guidelines: hemophilia and von Willebrand's disease. 2nd ed. Toronto: Association of Hemophilia Clinic Directors of Canada. 1999. Available from: URL: http://www.ahcdc.ca/vWD-Management.html (accessed October 2006).
38. Mannucci PM. Hemostatic drugs. N Engl J Med 1998; 339(1):245-53.
39. Sindet-Pedersen S, Stenbjerg S. Effect of local antifibrinolytic treatment with tranexamic acid in hemophiliacs undergoing oral surgery. J Oral Maxillofac Surg 1986; 44(9):703-7.
40. Sindet-Pedersen S, Ramstrom G, Bernvil S, Blomback M. Hemostatic effect of tranexamic acid mouthwash in anticoagulant-treated patients undergoing oral surgery. N Engl J Med 1989; 320(12):840-3.
41. Devani P, Lavery KM, Howell CJ. Dental extractions in patients on warfarin: is alteration of anticoagulant regime necessary? Br J Oral Maxillofac Surg 1998; 36(2):107-11.
42. Blinder D, Manor Y, Martinowitz U, Taicher S. Dental extractions in patients maintained on oral anticoagulant therapy: comparison of INR value with occurrence of postoperative bleeding. Int J Oral Maxillofac Surg 2001; 30(6):518-21.
43. Jeske AH, Suchko GD, ADA Council on Scientific Affairs and Division of Science; Journal of the American Dental Association. Lack of a scientific basis for routine discontinuation of oral anticoagulation therapy before dental treatment. J Am Dent Assoc 2003; 134(11):1492-97.
44. Wahl MJ. Myths of dental surgery in patients receiving anticoagulant therapy. J Am Dent Assoc 2000; 131(1):77-81.
45. Lockhart PB, Gibson J, Pond SH, Leitch J. Dental management considerations for the patient with an acquired coagulopathy. Part 2: Coagulopathies from drugs. Br Dent J 2003; 195(9):495-501.
46. Ardekian L, Gaspar R, Peled M, Brener B, Laufer D. Does low-dose aspirin therapy complicate oral surgical procedures? J Am Dent Assoc 2000; 131(3):331-35.
47. Seichshnaydre MA, Sismanis A, Hughes GB. Update of reparative granuloma: survey of the American Otological Society and the American Neurotology Society. Am J Otol 1994; 15(2):155-60.
48. Ereth MH, Dong Y, Gordon EA, Nuttall GA, Oliver WC. Microporous polysaccharide hemospheres provides effective topical hemostasis in a human modified bleeding time incision model. Presented at the Annual Meeting of the American Society of Anesthesiology, Orlando, Fla., 2002.
49. Zusman SP, Lustig JP, Baston I. Postextraction hemostasis in patients on anticoagulant therapy: the use of a fibrin sealant. Quintessence Int 1992; 23(10):713-6.
50. Ziccardi VB, Saini J, Demas PN, Braun TW. Management of the oral and maxillofacial surgery patient with end-stage renal disease. J Oral Maxillofac Surg 1992; 50(11):1207-12.
51. Lockhart PB, Gibson J, Pond SH, Leitch J. Dental management considerations for the patient with an acquired coagulopathy. Part 1: Coagulopathies from systemic disease. Br Dent J 2003; 195(8):439-45.
52. Rooney TP. General dentistry during continuous anticoagulation therapy. Oral Surg Oral Med Oral Pathol 1983; 56(3):252-5.
53. Zanon E, Martinelli F, Bacci C, Cordioli G, Girolami A. Safety of dental extractions among consecutive patients on oral anticoagulant treatment managed using a specific dental management protocol. Blood Coag Fibrinolysis 2003; 14(1):27-30.
54. Ramstrom G, Blomback M. Tooth extractions in hemophiliacs. Int J Oral Surg 1975; 4(1):1-7.
55. Souto JC, Oliver A, Zuazu-Jausoro I, Vives A, Fontcuberta J. Oral surgery in anticoagulated patients without reducing the dose of oral anticoagulant: a prospective randomized study. J Oral Maxillofac Surg 1996; 54(1):27-32.
56. Little JW, Falace DA, Miller CS, Rhodus NL. Dental management of the medically compromised patient. 6th ed. Mosby; 2002. p. 358-63.